BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 11994341)

  • 1. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial.
    Meunier PJ; Slosman DO; Delmas PD; Sebert JL; Brandi ML; Albanese C; Lorenc R; Pors-Nielsen S; De Vernejoul MC; Roces A; Reginster JY
    J Clin Endocrinol Metab; 2002 May; 87(5):2060-6. PubMed ID: 11994341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.
    Reginster JY; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S56-65. PubMed ID: 12730797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
    Reginster JY; Deroisy R; Dougados M; Jupsin I; Colette J; Roux C
    Osteoporos Int; 2002 Dec; 13(12):925-31. PubMed ID: 12459934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
    Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
    J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium ranelate in osteoporosis.
    Reginster JY
    Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
    Reginster JY; Deroisy R; Jupsin I
    Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
    Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ
    J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
    Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
    Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
    Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
    Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
    J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new treatment for post-menopausal osteoporosis: strontium ranelate.
    Rizzoli R
    J Endocrinol Invest; 2005; 28(8 Suppl):50-7. PubMed ID: 16323829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Liu JM; Wai-Chee Kung A; Pheng CS; Zhu HM; Zhang ZL; Wu YY; Xu L; Meng XW; Huang ML; Chung LP; Hussain NH; Sufian SS; Chen JL
    Bone; 2009 Sep; 45(3):460-5. PubMed ID: 19464401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.